Filing Flows › Health Care › Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals (RIGL) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Rigel Pharmaceuticals (RIGL) Q3 2026 earnings results →
Q3 2026 Revenue up 16% year over year to $80.9M · 16¢ of every $1 of revenue kept as net profit · operating margin 21.1%
Rigel Pharmaceuticals made $80.9M in Q3 2026 (+16% Y/Y): Product sales, net $72.3M, Contract revenues from collaborations and other $8.6M. Operating margin 21.1%, net earnings $13.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $80.9M in Q3 2026, up 16% year over year and up 3% from the previous quarter. Product sales, net was the largest line at 89% of revenue. Product sales, net added $8.2M year over year (up 13%), 72% of the total change.
Operating profit was $17.1M, a 21.1% margin (down 19.8 points year over year). Operating profit fell $11.3M even though revenue rose $11.4M versus Q3 2025, so costs grew faster than sales. Total costs grew 55% against revenue growth of 16%. The fastest-growing cost line was Research & development (+148%). Net earnings were $13.2M, down 53% year over year. The effective tax rate was 24.3%.
Operating cash flow was $34.6M (up 44% year over year), 262% of net earnings. Non-cash charges added back $1.8M of depreciation and amortization and $4.9M of share-based compensation. Working capital and other items added $14.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $80.9M | +16% | 21.1% | $13.2M | $34.6M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $78.7M | -23% | 30.0% | $17.3M | $30.7M |
| Q1 2026 | 10-Q | May 5, 2026 | $58.8M | +10% | 20.2% | $8.7M | $2.7M |
| Q4 2025 | 10-K | Mar 3, 2026 | $69.8M | +21% | 33.2% | $268M | $22.0M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $69.5M | +26% | 40.9% | $27.9M | $24.0M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $102M | +176% | 60.1% | $59.6M | $30.5M |
| Q1 2025 | 10-Q | May 6, 2025 | $53.3M | +81% | 23.9% | $11.4M | −$893K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- MCK — 42% of its revenue · Stated in 10-K (customer table) · source
- COR — 19% of its revenue · Stated in 10-K (customer table) · source
- CAH — 13% of its revenue · Stated in 10-K (customer table) · source
About Rigel Pharmaceuticals
We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms. TAVALISSE ® (fostamatinib disodium hexahydrate) is our first FDA-approved product and is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Japan, the Republic of Korea (Korea), Canada and Israel (as TAVALISSE) for the treatment of chronic ITP in adult patients.
In its own words, from its 10-K, filed Mar 3, 2026.
Rigel Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +16% against the peers' median +10%. Operating margin: 21.1% against the peers' median 21.1%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Q3 2026 | $80.9M | +16% | 21.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Rigel Pharmaceuticals 10-Q on SEC EDGAR · CIK 1034842 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns RIGL and who is buying
More on RIGL
- How Rigel Pharmaceuticals makes money: revenue by segment
- Rigel Pharmaceuticals next earnings date and what analysts expect
- Rigel Pharmaceuticals stock forecast, price target and fair value
- Who owns Rigel Pharmaceuticals stock: holders, funds and Congress trades
- Rigel Pharmaceuticals guidance and outlook
- Rigel Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Rigel Pharmaceuticals guidance history: guided vs reported
- Rigel Pharmaceuticals operating margin by quarter
- Rigel Pharmaceuticals net income by quarter
- Rigel Pharmaceuticals R&D spending by quarter
- Rigel Pharmaceuticals Product sales, net revenue by quarter
- Rigel Pharmaceuticals Contract revenues from collaborations and other revenue by quarter